linjc16/ctgov huggingface dataset:
Ultrasound Quantification of Liver Fat

Study Overview
=================
Brief Summary
-----------------
The investigators plan a prospective study designed to evaluate the accuracy of a new ultrasound method for quantification of liver fat content.

Detailed Description
-----------------
MRI proton density fat fraction (PDFF) will serve as the reference standard for liver fat fraction measurements. The strength of agreement between ultrasound derived fat fraction (UDFF) and PDFF will be the outcome of interest for this study.

Official Title
-----------------
Ultrasound Quantification of Liver Fat

Conditions
-----------------
Non-Alcoholic Fatty Liver Disease

Intervention / Treatment
-----------------
* Device: Magnetic Resonance Imaging (MRI)
* Device: Ultrasound Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 16 years of age or older with known fatty liver disease (based upon prior MRI or ultrasound), or at risk for fatty liver disease (obese). Exclusion Criteria: Subject under the age of 16 Pregnant subject Subjects who cannot cooperate with performance of the ultrasound exam Subjects who cannot cooperate with performance of the MRI exam Subjects who have contraindications to MRI Subjects who might require sedation or anesthesia to undergo study imaging

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepatic Steatosis<br><5% liver fat fraction by MRI PDFF | Device: Magnetic Resonance Imaging (MRI)<br>* Participants will undergo MR imaging of the liver. Liver PDFF will be measured.<br>Device: Ultrasound Imaging<br>* Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.<br>|
| No Hepatic Steatosis<br>>5% liver fat fraction by MRI PDFF | Device: Magnetic Resonance Imaging (MRI)<br>* Participants will undergo MR imaging of the liver. Liver PDFF will be measured.<br>Device: Ultrasound Imaging<br>* Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI PDFF correlation/agreement to UDFF | Liver fat % derived using MR PDFF will be compared to UDFF | Single time point-30 minute MRI/30 minute Ultrasound |
Study Evaluating HKI-272 Administered to Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.

Official Title
-----------------
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: neratinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: neratinib|HKI-272|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics; safety and tolerability; influence of food on the same. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer, Health, Pharmacokinetics, healthy subjects
Searching for the Liver Cancer-Related Biomarkers

Study Overview
=================
Brief Summary
-----------------
Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. Though regular sonographic examination can early detect small HCC and there are many therapeutic modalities for HCC, the therapeutic results remains unsatisfactory. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are used as the tumor markers for diagnosis of HCCs, these two markers are not good enough for the early detection of small HCCs. To improve the survival, further investigations of the early diagnostic markers are still needed. In this current project, we applied the proteomic method to identify the HCC biomarkers.

Detailed Description
-----------------
Cell lines Hep3B and Huh7 HCC cell lines will be cultured in (Dulbecco's modified Eagle medium) DMEM containing 10% fetal calf serum and incubated at 37 C in 5% CO2 incubator. The rationale of using HCC cell line instead of clinical HCC samples is that HCC tissues are heterogeneous and might contain some non-HCC cells. The cell will be harvested when cells reach 95% confluence. Sera collection 20 mL of venous 20 mL of venous blood was collected from 20 HBV-related HCC and 20 HCV-related HCC patients before treatment. The venous blood was allowed to clot, centrifuged at 800 g for 5 min, and serum was aliquoted and stored at -80 0C. Control sera were obtained from 20 HBV carriers without HCC, 20 chronic hepatitis C patients without HCC, and 10 normal subjects without liver diseases. Two-dimensional gel electrophoresis using patients' sera for immunoblotting will be done. Spots of interest will be identified by delayed extraction matrix-assisted laser desorption ionization.

Official Title
-----------------
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX

Conditions
-----------------
Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hepatocellular carcinoma Exclusion Criteria: multiple cancers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Breast Fat Grafting Augmentation in Chinese Women

Study Overview
=================
Brief Summary
-----------------
A total of 38 Chinese healthy women underwent autologous fat grafting for cosmetic breast augmentation. Breast volumes were measured by magnetic resonance imaging preoperatively and 1 year after the procedure. Furthermore, BREAST-Q was used to analyze the satisfaction and well-being of patients during the preoperative and 1 year post operation.

Detailed Description
-----------------
Autologous fat was obtained from thighs, waist or abdomen using resonance liposuction instrument. Fat was injected into the tissues in a multitunnel and multilayer way until they were firm and appeared fully tumesced according to the Coleman method.All MRI volume analyses were blindly performed by examiner independently preoperatively and 1 year postoperatively. Object marking was done using avanto 1.5T superconducting magnetic resonance scanner.Volume analysis was done by counting pixels within the frames of the MRI using ImageChecker CAD software.The Chinese version of BREAST-Q augmentation module was obtained from the Memorial Sloan-Kettering Cancer Center and the University of British Columbia. 38 patients were given the BREAST-Q questionnaire to express their thoughts preoperatively and 1 year postoperatively. Data were calculated using the Q-score program, which converts raw BREAST-Q scores of 1 through 4 or 5 to scores of 0 to 100.

Official Title
-----------------
Magnetic Resonance Imaging and Breast-Q Evaluation After Breast Autologous Fat Grafting Augmentation in Chinese Women

Conditions
-----------------
Breast Implantation

Intervention / Treatment
-----------------
* Procedure: Autologous Fat Grafting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women agreed to participate in the study Exclusion Criteria: Patients who had breast surgery previously Women on the lactation or gestation period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: fat graft<br>Autologous Fat Grafting | Procedure: Autologous Fat Grafting<br>* Autologous Fat Grafting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breast volumes were measured by magnetic resonance imaging |  | one year | 
| BREAST-Questionaire was used to analyze the satisfaction and well-being of patients |  | one year |
IOL Power Calculation Using Dual Schiempflug Analyzer

Study Overview
=================
Brief Summary
-----------------
This study evaluates the various ocular parameters which are necessary for ocular biometry and the calculated IOL powers using both dual Schiempflug analyzer and optical low-coherence refelctometry.

Detailed Description
-----------------
The measured keratometry, axial length, anterior chamber depth, lens thickness, white-to-white corneal diameter, and calculated IOL powers using various formulas including Hoffer Q, Holladay I, SRK II and SRK T measured by dual Schiempflug analyzer and optical low-coherence refelctometry will be compared.

Official Title
-----------------
Precision of Optical Biometry and Intraocular Lens Power Calculation Using Dual Schiempflug Analyzer

Conditions
-----------------
Cataract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: axial length between 21.0 and 27.0 mm older than 20 years old Exclusion Criteria: other ophthalmic diseases such as severe dry eye, glaucoma, and age-related macular degeneration previous ophthalmic surgery including cataract surgery, and refractive surgery very dense media which cannot be measured by the optical biometries severe zonulysis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular parameters | Parameters measured using two devices were compared at a single point | Single point | 
| Calculated IOL powers | Calculated IOL powers using two devices were compared at a single point | Single point | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dual Sheimpflug analyzer, intraocular lens power, optical low-coherence reflectometry
The Influence of Artificial Intelligence (AI )Assisted Polyp Detection (Discovery System) on Visual Gaze Patterns During Real-time Colonoscopy

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators aim to assess the influence of a computer-aided detection (CADe) system on the visual gaze patterns of endoscopists in order to further understand the effect of AI during real-time colonoscopy.

Official Title
-----------------
The Influence of Artificial Intelligence (AI) Assisted Polyp Detection (Discovery System) on Visual Gaze Patterns During Real-time Colonoscopy

Conditions
-----------------
Colonic Neoplasms

Intervention / Treatment
-----------------
* Device: eye-tracking glasses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria of patients: Referred for diagnostic, screening or surveillance colonoscopy Exclusion Criteria of patients: Therapeutic procedure Boston Bowel Prep Score (BBPS) score of <6
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Participating patients who undergo colonoscopy | |
| Endoscopists<br>Physicians performing colonoscopy | Device: eye-tracking glasses<br>* endoscopists wear eye-tracking glasses during real-time colonoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean gaze time per area of influence |  | End of colonoscopy |
Genetic Susceptibility to Radiation Induced Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973. This case control study, which is included in a larger european project, aims to investigate the DNA variant interacting with the risk of radiation induced thyroid cancer after irradiation. The sutdy is planed to include about 30 cases and 30 controls. Matching criteria are date of birth, gender, and age at irradiation.

Official Title
-----------------
Genetic Susceptibility to Radiation Induced Thyroid Cancer

Conditions
-----------------
Thyroid Neoplasms, Genetic Susceptibility, Radiation Exposure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diganosis of thyroid cancer during the followup or selected as a control matched on gender, date of birth and age at skin hemangioma diagnosis. Exclusion Criteria: No available adress Refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Differentiated thyroid carcinoma | Number of differentiated thyroid carcinoma occuring in a cohort of subjects treated for a skin hemangioma during the follow-up | From hemangioma diagnosis to the end of the followup, in average 45 years after hemangioma diagnosis |
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.

Official Title
-----------------
A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Primary Open Angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: LL-BMT1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, at least 18 years of age at the Screening Visit Diagnosed with primary open-angle glaucoma or ocular hypertension in both eyes At least one eye (called the study eye) must have an untreated intraocular pressure between 22 mmHg and 34 mmHg (inclusive) as measured at 9 am during the Baseline Visit. Best corrected visual acuity of Early Treatment Diabetic Retinopathy Study of 50 letters or better Exclusion Criteria: Glaucoma or optic neuropathy due to anything other than above noted reasons Cup-to-disc ratio of >0.8 in either eye Corneal thickness <480 or >620 μm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Open-label, non-comparative
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LL-BMT1<br>Group 4 extended-wear contact lens printed with bimatoprost | Drug: LL-BMT1<br>* Drug-printed contact lens in both eyes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Event Rate | Number of subjects with adverse events | Day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular Pressure Elevation | Number of subjects with IOP elevation >= 5 mm Hg in study eye | Day 7 | 
| IOP Changes | Mean change in IOP from baseline in study eye (mm Hg) on Day 1, 4 pm | Days 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Prostaglandin, Intraocular pressure
Brain Imaging: Cocaine Effects & Medication Development - 5

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Official Title
-----------------
Brain Imaging: Cocaine Effects & Medication Development

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Cocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cocaine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change in rCBF at 5 & 15 minutes (Xe) |  |  | 
| Relative change in rCBF at 5, 19, & 33 minutes (O15) |  |  | 
| Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine
A Comparison of Telemedical and Conventional Antihypertensive Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare telemedical antihypertensive treatment based on home blood pressure monitoring and conventional antihypertensive treatment based on monitoring of blood pressure in the doctor's office. We want to test the hypotheses that telemedical treatment is more effective in lowering blood pressure, provide better quality of life and is more cost-effective.

Official Title
-----------------
A Comparison of Telemedical and Conventional Antihypertensive Treatment

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Device: Telemedical blood pressure monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 20 - 80 years office blood pressure > 150/95 mmHg or systolic blood pressure >150 mmHg and diastolic blood pressure < 90 mmHg Exclusion Criteria: not able to perform home blood pressure measurements low compliance abuse of alcohol/ medicine unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Home blood pressure telemonitoring<br> | Device: Telemedical blood pressure monitoring<br>* Measurement of home blood pressure, three times per week for three months and once a week for three months.<br>|
| No Intervention: Conventional blood pressure monitoring<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in Number of Patients Who Reached Target Blood Pressure |  | 6 months | 
| Difference in Mean Daytime Systolic Ambulatory Blood Pressure From Baseline to Follow-up After Six Months | Comparison of mean change in daytime systolic ambulatory blood pressure from baseline to follow up after 6 months between the two groups | baseline and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Telemedicine, Blood pressure, Quality of life, Cost-effectiveness
The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Study Overview
=================
Brief Summary
-----------------
Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased platelet destruction due to presence of anti-platelet antibodies. Hepatitis C virus infection, which is one of the most common chronic viral infections worldwide, may cause secondary chronic immune thrombocytopenic purpura. It seemed to play a pathogenic role in autoimmune thrombocytopenic purpura. Moreover, the successful response (negative hepatitis C virus - ribonucleic acid) to tapered steroids and antiviral therapy was useful to revert thrombocytopenia

Official Title
-----------------
The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Drug: sofosbuvir daclatasvir
* Drug: Ledipasvir/sofosbuvir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hepatitis C virus infection and thrombocytopenia before treatment Exclusion Criteria: Infection Hepatitis B virus Hypersplenism Diseases affecting Bone marrow Major clotting factors abnormalities eg. Disseminated intravascular coagulopathy, severe Prothrombin deficiency
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study group<br>Hepatitis- C virus with thrombocytopenia | Drug: sofosbuvir daclatasvir<br>* oral tablets<br>Drug: Ledipasvir/sofosbuvir<br>* oral tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the mean difference on the platelet count |  | 6 month |